Activity
1.Measured in a cell proliferation assay using Balb/3T3 mouse embryonic fibroblast cells. The ED50 for this effect is typically 0.1-0.6 ng/mL.2.Human intestinal cancer organoids were cultured with RSPO1(Cat#11083-HNAS), EGF(Cat#50482-MNCH), NOG(Cat#50688-M02H). (Routinely tested). Data provided by D1 Medical Technology.3.Human colorectum organoids were cultured with RSPO1(Cat#11083-HNAS), EGF(Cat#50482-MNCH), NOG(Cat#50688-M02H). (Routinely tested). Data provided by D1 Medical Technology.4.Human lung cancer organoids were cultured with FGF2(Cat#10014-HNAE), FGF4(Cat#16043-HNAE), FGF7(Cat#10210-H07E), EGF(Cat#50482-MNCH), FGF10(Cat#10573-HNAE), NOG(Cat#50688-M02H), RSPO1(Cat#11083-HNAS). (Routinely tested). Data provided by D1 Medical Technology.5.Human lung organoids were cultured with FGF2(Cat#10014-HNAE), FGF4(Cat#16043-HNAE), FGF7(Cat#10210-H07E), EGF(Cat#50482-MNCH), FGF10(Cat#10573-HNAE), NOG(Cat#50688-M02H), RSPO1(Cat#11083-HNAS). (Routinely tested). Data provided by D1 Medical Technology.6.Human cholangiocarcinomas organoids were cultured with FGF2(Cat#10014-HNAE), HGF(Cat#10463-HNAS), FGF7(Cat#10210-H07E), EGF(Cat#50482-MNCH), FGF10(Cat#10573-HNAE), NOG(Cat#50688-M02H), RSPO1(Cat#11083-HNAS). (Routinely tested). Data provided by D1 Medical Technology.7.Human liver cancer organoids were cultured with FGF2(Cat#10014-HNAE), HGF(Cat#10463-HNAS), FGF7(Cat#10210-H07E), EGF(Cat#50482-MNCH), FGF10(Cat#10573-HNAE), TGFB1(Cat#10804-HNAC), NOG(Cat#50688-M02H), RSPO1(Cat#11083-HNAS). (Routinely tested). Data provided by D1 Medical Technology.8.Human kidney cancer organoids were cultured with FGF2(Cat#10014-HNAE), FGF7(Cat#10210-H07E), EGF(Cat#50482-MNCH), FGF10(Cat#10573-HNAE), NOG(Cat#50688-M02H), RSPO1(Cat#11083-HNAS). (Routinely tested). Data provided by D1 Medical Technology.9.Human kidney organoids were cultured with FGF7(Cat#10210-H07E), EGF(Cat#50482-MNCH), FGF10(Cat#10573-HNAE), NOG(Cat#50688-M02H), RSPO1(Cat#11083-HNAS), HGF(Cat#10463-HNAS), FGF4(Cat#16043-HNAE). (Routinely tested). Data provided by D1 Medical Technology.10.Human gastric cancer organoids were cultured with EGF(Cat#50482-MNCH), FGF10(Cat#10573-HNAE), NOG(Cat#50688-M02H), RSPO1(Cat#11083-HNAS). (Routinely tested). Data provided by D1 Medical Technology.11.Human stomach organoids organoids were cultured with EGF(Cat#50482-MNCH), FGF10(Cat#10573-HNAE), NOG(Cat#50688-M02H), RSPO1(Cat#11083-HNAS). (Routinely tested). Data provided by D1 Medical Technology.12.Human breast cancer organoids were cultured with FGF7(Cat#10210-H07E), RSPO1(Cat#11083-HNAS), IGF1(Cat#10598-HNAE), EGF(Cat#50482-MNCH), NRG1 Beta 1(Cat#11609-H01H), NOG(Cat#50688-M02H). (Routinely tested). Data provided by D1 Medical Technology.13.Human ovarian organoids were cultured with IGF1(Cat#10598-HNAE), NRG1 Beta 1(Cat#11609-H01H), RSPO1(Cat#11083-HNAS), EGF(Cat#50482-MNCH), NOG(Cat#50688-M02H). (Routinely tested). Data provided by D1 Medical Technology.14.Human small intestinal organoids were cultured with IL22(Cat#13059-HNAE), FGF10(Cat#10573-HNAE), EGF(Cat#50482-MNCH), NOG(Cat#50688-M02H). (Routinely tested). Data provided by D1 Medical Technology.